THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [5.21] ID: TIP-MED-000089

Rifaximin & L-Ornithine L-Aspartate (LOLA)

Active Ingredient / Scientific Identity: Rifaximin & L-Ornithine L-Aspartate • Class: Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H)

⚖️ Compare Profile
THE INDIAN PHARMACIST — Educational Reference Sheet
Profile: Rifaximin & L-Ornithine L-Aspartate (LOLA) ([5.21] | ID: TIP-MED-000089) • Last Reviewed: 2026-11-10
Source URL: https://theindianpharmacist.com/medicine/5-21-rifaximin-l-ornithine-l-aspartate-lola/
Generic / Entity NameRifaximin & L-Ornithine L-Aspartate (LOLA) ([5.21])
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassNon-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Sche
Available Dosage FormsRifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
Regulatory ClassificationSchedule H Prescription Drug (To be sold by retail on the prescription of a Registere
Key Warning & Review DateRenal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicate
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Schedule H Prescription Drug (To be sold by retail o✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

Rifaximin & L-Ornithine L-Aspartate (LOLA) (TIP-MED-000089, Reference Code [5.21]) is classified under Gastrointestinal & Hepatobiliary Medicines (Ch 05) as a Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H). Within the Indian regulatory and compendial framework, it is governed under Schedule H Prescription Drug (To be sold by retail on the prescription of a Registered Medical Practitioner only — Drugs Rules 1945).

Verified Indian Market Examples / Compendial Status:
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.21], p. 70): Rifaximin: Rcifax (Lupin), Rifagut (Sun), Torfix (Torrent). LOLA: Hepa-Merz (Win-Medicare), Hepa-Sachet — Strengths & Dosage Forms: Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
Representative Indian Market Examples (Edition 2.7 Ch 05 [5.21], p. 70): Rifaximin: Rcifax (Lupin), Rifagut (Sun), Torfix (Torrent). LOLA: Hepa-Merz (Win-Medicare), Hepa-Sachet — Strengths & Dosage Forms: Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
Dosage Forms & Available Strengths:
Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule
Routes: Oral / Parenteral / Topical as specified by formulation

3. Mechanism of Action & Pharmacodynamics

Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H) acting on target receptor/enzyme pathways in Gastrointestinal & Hepatobiliary Medicines (Ch 05): clinical efficacy is mediated via Non-Absorbable Luminal Rifamycin Antibiotic & Ammonia-Detoxifying Amino Acid Complex (Schedule H) for Overt & covert Hepatic Encephalopathy (secondary prophylaxis alongside Lactulose in decompensated cirrhosis); Rifaximin 400/550 mg TDS x 14d is also used for diarrhoea-predominant IBS (IBS-D) and non-invasive traveller's diarrhoea.

4. Therapeutic Indications & Evidence-Supported Uses

  • Overt & covert Hepatic Encephalopathy (secondary prophylaxis alongside Lactulose in decompensated cirrhosis)
  • Rifaximin 400/550 mg TDS x 14d is also used for diarrhoea-predominant IBS (IBS-D) and non-invasive traveller's diarrhoea

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: Hepatic Encephalopathy: Rifaximin 550 mg PO BD (or 400 mg TDS) continuously alongside Lactulose (titrated to 2–3 soft stools/day) + LOLA 1–2 sachets (3–6 g) dissolved in water PO BD–TDS. Traveller's Diarrhoea: Rifaximin 200 mg TDS x 3d

Administration & Meal Timing: Rifaximin may be taken with or without food; dissolve LOLA granules in a glass of water/juice and drink with or after meals | Morning & Evening (BD for Rifaximin 550 mg) or TDS (400 mg / LOLA)

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Absorption, distribution, metabolism, and excretion follow class pharmacokinetic profile; verify patient renal/hepatic function.
Metabolism & Biotransformation:
Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy
Elimination & Renal Adjustment:
Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy
Hepatic Impairment Considerations:
Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • Rifaximin: Contraindicated in invasive febrile/bloody dysentery (<0.4% systemic absorption, so ineffective for systemic infections!). LOLA: Contraindicated in severe renal failure (Serum Creatinine >3.0 mg/dL)!

Key Clinical Precautions: Renal: Rifaximin requires no renal adjustment; LOLA is CONTRAINDICATED if SCr >3.0 mg/dL (eGFR <20 mL/min). Hepatic: Indicated in hepatic encephalopathy

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Flatulence, mild abdominal pain, headache, peripheral oedema; LOLA IV >5 g/h causes nausea/vomiting
  • In Child–Pugh C cirrhosis, systemic exposure of Rifaximin increases 10–20-fold (caution with P-gp inhibitors); rare C. difficile colitis
Serious / Dose-Limiting Adverse Effects:
  • Monitor for severe hypersensitivity, organ toxicity, or dose-limiting adverse events.

9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

  • Cyclosporine (potent P-gp/OATP inhibitor) increases systemic Rifaximin AUC 80–120-fold; monitor INR if on Warfarin

10. Clinical Monitoring, Patient Counselling & Storage

Clinical & Laboratory Monitoring: Monitor clinical response, baseline renal/hepatic parameters, and relevant serum biomarkers.

Pharmacist Patient Counselling Points:

  • Patient Counselling Checklist: Rifaximin acts locally inside the intestine to stop gut bacteria from producing ammonia gas that clouds the brain; continue taking alongside Lactulose every day even when feeling clear-headed
  • Meal & Clock Timing Instruction: Rifaximin may be taken with or without food; dissolve LOLA granules in a glass of water/juice and drink with or after meals (Morning & Evening (BD for Rifaximin 550 mg) or TDS (400 mg / LOLA))
  • Missed Dose Protocol: Take as soon as remembered; never stop Rifaximin or Lactulose abruptly in cirrhosis (precipitates hepatic coma!)
  • Geriatric Dispensing Pearl: Screen older cirrhotic patients for constipation, dehydration, diuretic hypokalaemia, or sedatives (BZDs) as triggers of encephalopathy

Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Rifaximin Tablets: 200 mg, 400 mg, 550 mg. LOLA: 3 g / 5 g Oral Granule Sachets; 5 g/10 mL IV Ampoule

11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

12. Authoritative References, Regulatory Sources & Editorial Disclaimer

Primary Compendial & Guideline Reference: Indian Pharmacist Desk Reference — Professional Edition 2.7 (2026–27) • Ch 05 [5.21] (p. 70)

Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: HANDBOOK_SOURCE_CONTENT

Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.

← Back to All 644 Reference Profiles 📖 Explore 40 Knowledge Hub Articles → ✉️ Report Errata / Feedback
Educational Reference Notice: This printout from THE INDIAN PHARMACIST (https://theindianpharmacist.com/medicine/5-21-rifaximin-l-ornithine-l-aspartate-lola/, Last Reviewed: 2026-11-10) is an educational reference sheet for students and healthcare learners. It is NOT an official prescribing guideline or patient-specific treatment order.